Semaglutide Side Effects

This is the molecule-level piece, sitting alongside the product-specific versions for Ozempic, Wegovy and oral Wegovy, and under the class-wide Side Effects Nobody Preps You For.

The profile belongs to the molecule, not the route

Start here, because it corrects the most common misconception I encounter.

People assume a tablet will be easier on the stomach than an injection. It is not. The gastrointestinal effects of semaglutide come from the mechanism — delayed gastric emptying, plus central appetite signalling — and the mechanism does not care how the molecule got into you.

An oral formulation solves a needle problem. It does not solve a nausea problem. What it does avoid is injection-site reactions, and what it adds is a set of strict dosing conditions that determine how much you absorb.

Likewise, Ozempic and Wegovy are the same molecule. The differences in reported rates between their trials are largely differences in dose and in the populations studied, not differences in the drug.

What to expect

Very common: nausea, constipation, diarrhoea, vomiting, abdominal pain, reflux, sulfurous burping, fatigue, headache. Dose-dependent, clustered around escalations, settling within about a week at a stable dose.

The timing is predictable. Blood levels peak 1–3 days after a subcutaneous injection, which is why the worst day is typically day two or three rather than injection day. That single fact reframes the first 3 months for most people, and I have written about the pharmacokinetics behind it.

Uncommon and worth knowing precisely: gallbladder disease (rapid weight loss raises gallstone risk from any cause), pancreatitis (rare, but the reason for the severe-abdominal-pain instruction), dehydration and kidney injury (almost always downstream of vomiting or diarrhoea rather than a direct effect).

Absolute contraindications: personal or family history of medullary thyroid carcinoma, or multiple endocrine neoplasia type 2. Not a judgement call. I have set out the full screening list in Who Should Not Take a GLP-1.

The vial problem

I want to give this its own section, because on this molecule specifically it is the most likely route to serious harm — and it has nothing to do with pharmacology.

I am not going to lecture anyone about compounded products. The gap between what these drugs cost and what people can pay is a policy failure, and the people caught in it did not create it. What follows is clinical rather than moral.

Compounded semaglutide concentrations vary between compounders. A vial is not a standard unit. Two that look identical can contain different milligrams per millilitre.

Which means a dose recorded as “20 units” is meaningless without the concentration it was drawn from. And units-versus-milligram confusion — reading an insulin syringe’s unit markings as though they were milligrams — has produced overdoses serious enough for the FDA to communicate about them. People have been hospitalised with protracted vomiting and dehydration from a tenfold error.

If you are using a vial: record the concentration, the volume drawn, and the resulting dose in milligrams, every single time. If you cannot state your dose in milligrams, do not take the next injection until you have asked your prescriber. That instruction is worth more than everything else on this page.

The long game

Two issues that only appear on courses measured in years, and that nobody warns you about at the start.

Nutrient inadequacy. The arithmetic is simple and unforgiving: food volume falls by half, requirements do not fall at all. Iron, B12, vitamin D and calcium all become harder to hit. Check ferritin specifically — a normal haemoglobin does not rule out depleted stores.

Lean mass. The drug handles appetite and has no opinion about which tissue you lose. Protein at 1.2–1.6 g/kg/day and resistance training at least twice weekly are what change the ratio.

Managing the manageable part

Slow the titration. The single most effective intervention, and the most under-used. The label permits it explicitly.

Eat for the window. Smaller meals, less fat, nothing fried, in the 2–3 days after the dose.

Treat constipation early rather than enduring it. It causes more discontinuation than nausea does.

Work from your own pattern rather than a generic list. Everything above is population-level. Your version is specific, reproducible, and only discoverable from a record.

This is where I think structured management earns its keep, and it is why I use the Zenday App. It takes your logged dose timing and symptoms and builds a personalised plan for minimising your side effects — protocols written by its clinical team, applied to your actual pattern rather than the average one. More than a million people use it.

The argument for that on this particular page is straightforward: side effects are among the most common reasons people abandon semaglutide, and the abandonment overwhelmingly happens in the first 3 months, to people who were experiencing something ordinary and self-limiting and had no way to know it. Anticipating day three beats treating day three.

And the boundary matters as much as the feature: it manages tolerability. It is not a substitute for your prescriber, and no red flag should ever be routed through it.

The red flags

• Severe, persistent abdominal pain radiating to the back — possible pancreatitis. Stop and seek care.
• Right-upper-quadrant pain, fever, jaundice — possible gallbladder disease.
• Vomiting or diarrhoea you cannot keep ahead of.
• Any procedure with sedation — tell the anaesthetist, unprompted.
• On a vial: any uncertainty about your dose in milligrams.

For orientation: semaglutide’s half-life is about 7 days, steady state arrives at 4–5 weeks, escalations come at 4 week intervals, and symptoms usually peak in the 1–2 weeks after each one. Protein wants 1.2–1.6 g/kg a day throughout.